4.8 Review

Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions

Journal

FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.979414

Keywords

RGC-32; multiple sclerosis; EAE (experimental autoimmune encephalomyelitis); radial glia; neuroinflammation; astrocyte; Th17

Categories

Funding

  1. Veterans Administration Merit Award [I01BX001458]
  2. UEFISCDI, Romania [RO1 NS42011]
  3. UEFISCDI, Romania [PN-III-P4-PCE-2021-0333]

Ask authors/readers for more resources

Recent studies have highlighted the significant role of reactive astrocytes in multiple sclerosis (MS). The gene RGC-32, induced by complement activation, growth factors, and cytokines, is found to play a crucial role in the differentiation of Th17 cells and in regulating gene expression in astrocytes. RGC-32 promotes the formation of reactive astrocytes and has the potential to be a biomarker and therapeutic target for MS.
Recent advances in understanding the pathogenesis of multiple sclerosis (MS) have brought into the spotlight the major role played by reactive astrocytes in this condition. Response Gene to Complement (RGC)-32 is a gene induced by complement activation, growth factors, and cytokines, notably transforming growth factor beta, that is involved in the modulation of processes such as angiogenesis, fibrosis, cell migration, and cell differentiation. Studies have uncovered the crucial role that RGC-32 plays in promoting the differentiation of Th17 cells, a subtype of CD4(+) T lymphocytes with an important role in MS and its murine model, experimental autoimmune encephalomyelitis. The latest data have also shown that RGC-32 is involved in regulating major transcriptomic changes in astrocytes and in favoring the synthesis and secretion of extracellular matrix components, growth factors, axonal growth molecules, and pro-astrogliogenic molecules. These results suggest that RGC-32 plays a major role in driving reactive astrocytosis and the generation of astrocytes from radial glia precursors. In this review, we summarize recent advances in understanding how RGC-32 regulates the behavior of Th17 cells and astrocytes in neuroinflammation, providing insight into its role as a potential new biomarker and therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available